<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Antiprotozoal therapies</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Antiprotozoal therapies</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Antiprotozoal therapies</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Peter F Weller, MD, MACP</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Karin Leder, MBBS, FRACP, PhD, MPH, DTMH</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Milana Bogorodskaya, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Oct 31, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Protozoan parasites belong to four distinct groups: the amebae, the flagellates, the ciliates, and the sporozoa. Protozoa are single-celled organisms that replicate by various mechanisms within the infected host. The mechanisms of action of the various agents used to treat protozoan parasites are relatively poorly understood [<a href="#rid1">1,2</a>].</p><p>In the United States, the antiprotozoal drugs eflornithine, <a class="drug drug_general" data-topicid="126253" href="/z/d/drug information/126253.html" rel="external">melarsoprol</a>, and <a class="drug drug_general" data-topicid="10291" href="/z/d/drug information/10291.html" rel="external">suramin</a> are available through the Centers for Disease Control and Prevention (CDC) Drug Service, Atlanta, GA 30333 (telephone 404-639-3670; <a class="__cf_email__" data-cfemail="f490868193879186829d9791b4979097da939b82" href="/cdn-cgi/l/email-protection">[email protected]</a>). </p><p>Agents with activity against protozoal parasites will be reviewed here; their use for treatment of specific protozoal infections is discussed in detail separately. Antimalarial agents are discussed in detail separately, as are agents with activity against helminths. (See  <a class="medical medical_review" href="/z/d/html/468.html" rel="external">"Antimalarial drugs: An overview"</a> and  <a class="medical medical_review" href="/z/d/html/487.html" rel="external">"Anthelminthic therapies"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">ALBENDAZOLE</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9371" href="/z/d/drug information/9371.html" rel="external">Albendazole</a> binds to tubulin and affects cytoskeletal microtubules and is a well-established therapy treatment of helminthic infections [<a href="#rid3">3</a>]. (See  <a class="medical medical_review" href="/z/d/html/487.html" rel="external">"Anthelminthic therapies"</a>.)</p><p><a class="drug drug_general" data-topicid="9371" href="/z/d/drug information/9371.html" rel="external">Albendazole</a> also has activity against some protozoan infections, including most microsporidial species, particularly <em>Encephalitozoon</em> infections. However, it is not as active against <em>Enterocytozoon bieneusi</em> [<a href="#rid4">4-11</a>]. (See  <a class="medical medical_review" href="/z/d/html/5731.html" rel="external">"Microsporidiosis"</a>.)</p><p>Absorption of <a class="drug drug_general" data-topicid="9371" href="/z/d/drug information/9371.html" rel="external">albendazole</a> is enhanced by taking it with fatty meals. Albendazole should be taken with fatty foods for treatment of invasive systemic parasitic infections; it should be taken with no food (eg, on an empty stomach) for treatment of intraluminal parasitic infections with no systemic involvement.</p><p class="headingAnchor" id="H3"><span class="h1">ATOVAQUONE</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8957" href="/z/d/drug information/8957.html" rel="external">Atovaquone</a> is a hydroxynaphthoquinone agent active against several protozoan parasites [<a href="#rid12">12</a>].</p><p>For the treatment of <em>Pneumocystis jirovecii</em> (formerly <em>carinii</em>) pneumonia (PCP), <a class="drug drug_general" data-topicid="8957" href="/z/d/drug information/8957.html" rel="external">atovaquone</a> is well tolerated but less effective than <a class="drug drug_general" data-topicid="9752" href="/z/d/drug information/9752.html" rel="external">pentamidine</a> or <a class="drug drug_general" data-topicid="9785" href="/z/d/drug information/9785.html" rel="external">trimethoprim-sulfamethoxazole</a> (TMP-SMX). Atovaquone is an alternative agent for prophylaxis against PCP for patients who are unable to tolerate TMP-SMX. (See  <a class="medical medical_review" href="/z/d/html/1406.html" rel="external">"Epidemiology, clinical manifestations, and diagnosis of Pneumocystis pneumonia in patients without HIV"</a> and  <a class="medical medical_review" href="/z/d/html/3709.html" rel="external">"Treatment and prevention of Pneumocystis infection in patients with HIV"</a>.)</p><p>Atovaquone-pyrimethamine is an alternative agent for treatment and long-term maintenance therapy of <em>Toxoplasma </em>encephalitis in AIDS patients intolerant of sulfonamides. (See  <a class="medical medical_review" href="/z/d/html/3747.html" rel="external">"Overview of prevention of opportunistic infections in patients with HIV"</a> and  <a class="medical medical_review" href="/z/d/html/3710.html" rel="external">"Toxoplasmosis in patients with HIV"</a>.)</p><p><a class="drug drug_general" data-topicid="8704" href="/z/d/drug information/8704.html" rel="external">Atovaquone-proguanil</a> may be used for malaria chemoprophylaxis and is also effective in the treatment of <em>Plasmodium falciparum</em> malaria. (See  <a class="medical medical_review" href="/z/d/html/468.html" rel="external">"Antimalarial drugs: An overview"</a>.)</p><p>Atovaquone-azithromycin may be used for treatment of babesiosis. (See  <a class="medical medical_review" href="/z/d/html/5670.html" rel="external">"Babesiosis: Clinical manifestations and diagnosis"</a>.)</p><p><a class="drug drug_general" data-topicid="8957" href="/z/d/drug information/8957.html" rel="external">Atovaquone</a> suspension is twice as well absorbed as the tablet form, and consumption of atovaquone with a fatty meal enhances absorption [<a href="#rid13">13</a>].</p><p class="headingAnchor" id="H4"><span class="h1">BENZNIDAZOLE</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="114673" href="/z/d/drug information/114673.html" rel="external">Benznidazole</a> is a nitroimidazole derivative with activity against <em>Trypanosoma cruzi</em> trypomastigotes and amastigotes. Side effects include rash, nausea, and peripheral neuritis. (See  <a class="medical medical_review" href="/z/d/html/14004.html" rel="external">"Chagas disease: Antitrypanosomal drug therapy"</a>.)</p><p class="headingAnchor" id="H5"><span class="h1">EFLORNITHINE</span><span class="headingEndMark"> — </span>Eflornithine inhibits parasite growth by selective and irreversible inhibition of ornithine carboxylase, an enzyme required for cellular proliferation and differentiation [<a href="#rid14">14,15</a>]. It is effective in the early and late central nervous system stage of infections with <em>Trypanosoma brucei gambiense </em>but not <em>T. b. rhodesiense</em>. (See  <a class="medical medical_review" href="/z/d/html/5697.html" rel="external">"Human African trypanosomiasis: Epidemiology, clinical manifestations, and diagnosis"</a>.)</p><p>Frequent side effects include diarrhea, anemia, leukopenia, and hair loss.</p><p class="headingAnchor" id="H3695244700"><span class="h1">FEXINIDAZOLE</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="132112" href="/z/d/drug information/132112.html" rel="external">Fexinidazole</a>, a nitroimidazole derivate, was approved for treatment of gambiense human African trypanosomiasis (HAT) by the European Medicines Agency in 2018, under a mechanism for drugs intended for use outside the European Union [<a href="#rid16">16,17</a>]. It was approved by the US Food and Drug Administration in 2021 [<a href="#rid18">18</a>]. </p><p>Oral administration is a major advantage of <a class="drug drug_general" data-topicid="132112" href="/z/d/drug information/132112.html" rel="external">fexinidazole</a>, with greater convenience and lower cost relative to other agents for treatment of HAT that require intravenous or intramuscular administration. (See  <a class="medical medical_review" href="/z/d/html/5688.html" rel="external">"Human African trypanosomiasis: Treatment and prevention"</a>.)</p><p class="headingAnchor" id="H6"><span class="h1">FUMAGILLIN</span><span class="headingEndMark"> — </span>Fumagillin is an antibiotic released by <em>Aspergillus fumigatus</em>. The mechanism of action of fumagillin has not been established, but the drug can suppress proliferation of microsporidia in vitro [<a href="#rid19">19</a>].</p><p>Topical fumagillin therapy has been successful in several cases of microsporidial keratoconjunctivitis in patients with AIDS. Fumagillin has also been used to treat intestinal <em>E. bieneusi</em> infections in immunocompromised patients; neutropenia and thrombocytopenia are common complications. (See  <a class="medical medical_review" href="/z/d/html/5731.html" rel="external">"Microsporidiosis"</a>.)</p><p class="headingAnchor" id="H7"><span class="h1">FURAZOLIDONE</span><span class="headingEndMark"> — </span>Furazolidone is a nitrofuran derivative used as an alternative drug for giardiasis. Adverse effects include nausea, vomiting, and allergic reactions [<a href="#rid20">20</a>]. The drug is a monoamine oxidase inhibitor and also causes a disulfiram-like reaction when taken with alcohol. Furazolidone is not bitter (unlike other drugs for giardiasis) and is available in a liquid form useful for young children. (See  <a class="medical medical_review" href="/z/d/html/6024.html" rel="external">"Giardiasis: Treatment and prevention"</a>.)</p><p class="headingAnchor" id="H9"><span class="h1">MELARSOPROL</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="126253" href="/z/d/drug information/126253.html" rel="external">Melarsoprol</a> is a trivalent arsenical compound used to treat late-stage African trypanosomiasis involving the central nervous system [<a href="#rid21">21</a>]. Melarsoprol appears to act by binding to essential thiol groups of trypanosomes, preventing trophozoite multiplication [<a href="#rid14">14,22</a>]. Severe adverse effects are common, including myocarditis, encephalopathy, and hypersensitivity reactions [<a href="#rid23">23</a>]. (See  <a class="medical medical_review" href="/z/d/html/5697.html" rel="external">"Human African trypanosomiasis: Epidemiology, clinical manifestations, and diagnosis"</a>.)</p><p class="headingAnchor" id="H10"><span class="h1">METRONIDAZOLE</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">Metronidazole</a> is a 5-nitroimidazole with potent activity against several protozoa including <em>Entamoeba histolytica</em>, <em>Giardia duodenalis</em>, and <em>Trichomonas vaginalis</em>. Metronidazole is the drug of choice for giardiasis and intestinal and extraintestinal amebiasis and trichomoniasis. (See  <a class="medical medical_review" href="/z/d/html/5727.html" rel="external">"Intestinal Entamoeba histolytica amebiasis"</a> and  <a class="medical medical_review" href="/z/d/html/5728.html" rel="external">"Extraintestinal Entamoeba histolytica amebiasis"</a> and  <a class="medical medical_review" href="/z/d/html/6024.html" rel="external">"Giardiasis: Treatment and prevention"</a> and  <a class="medical medical_review" href="/z/d/html/5453.html" rel="external">"Trichomoniasis: Clinical manifestations and diagnosis"</a>.)</p><p><a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">Metronidazole</a> is generally well tolerated; adverse effects include mild abdominal pain, headache, nausea, and metallic taste. It produces a disulfiram-like reaction when taken with alcohol. (See  <a class="medical medical_review" href="/z/d/html/464.html" rel="external">"Metronidazole: An overview"</a>.)</p><p class="headingAnchor" id="H11"><span class="h1">NIFURTIMOX</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="126252" href="/z/d/drug information/126252.html" rel="external">Nifurtimox</a> is a synthetic nitrofuran compound for treatment of acute <em>T. cruzi</em> infection. The drug has little effect in chronic Chagas disease. (See  <a class="medical medical_review" href="/z/d/html/5700.html" rel="external">"Chagas gastrointestinal disease"</a> and  <a class="medical medical_review" href="/z/d/html/4925.html" rel="external">"Chronic Chagas cardiomyopathy: Management and prognosis", section on 'Antitrypanosomal therapy'</a>.)</p><p><a class="drug drug_general" data-topicid="126252" href="/z/d/drug information/126252.html" rel="external">Nifurtimox</a> can be used in combination with eflornithine or <a class="drug drug_general" data-topicid="126253" href="/z/d/drug information/126253.html" rel="external">melarsoprol</a> for treatment of African trypanosomiasis due to <em>T. b. gambiense</em>. (See  <a class="medical medical_review" href="/z/d/html/5688.html" rel="external">"Human African trypanosomiasis: Treatment and prevention"</a>.)</p><p>Adverse reactions are common and dose dependent, including nausea, vomiting, insomnia, headache, vertigo, tremor, paresthesias, and convulsions [<a href="#rid23">23</a>].</p><p class="headingAnchor" id="H12"><span class="h1">NITAZOXANIDE</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="10105" href="/z/d/drug information/10105.html" rel="external">Nitazoxanide</a> is a nitrothiazolyl-salicylamide derivative useful for treatment diarrhea due to <em>Cryptosporidium parvum</em> in children and for the treatment of giardiasis in children and adults [<a href="#rid24">24</a>]. It is generally well tolerated. (See  <a class="medical medical_review" href="/z/d/html/6024.html" rel="external">"Giardiasis: Treatment and prevention"</a>.)</p><p><a class="drug drug_general" data-topicid="10105" href="/z/d/drug information/10105.html" rel="external">Nitazoxanide</a> has not been shown to be more effective than placebo in HIV-infected patients; prolonged therapy at higher doses may be required. (See  <a class="medical medical_review" href="/z/d/html/5733.html" rel="external">"Cryptosporidiosis: Epidemiology, clinical manifestations, and diagnosis"</a>.)</p><p class="headingAnchor" id="H13"><span class="h1">PAROMOMYCIN</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9742" href="/z/d/drug information/9742.html" rel="external">Paromomycin</a> is an oral poorly absorbed aminoglycoside. It is used as a secondary drug for treatment of noninvasive amebiasis. (See  <a class="medical medical_review" href="/z/d/html/5727.html" rel="external">"Intestinal Entamoeba histolytica amebiasis"</a>.)</p><p>It may also be used for the treatment of giardiasis during pregnancy when the disease is not severe enough to require definitive therapy with <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">metronidazole</a> or quinacrine. (See  <a class="medical medical_review" href="/z/d/html/6024.html" rel="external">"Giardiasis: Treatment and prevention"</a>.)</p><p class="headingAnchor" id="H14"><span class="h1">PENTAMIDINE</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9752" href="/z/d/drug information/9752.html" rel="external">Pentamidine</a> isethionate is an aromatic diamine compound active against <em>Pneumocystis</em> and several protozoal pathogens including <em>Leishmanii</em> spp and <em>T. b. gambiense </em>[<a href="#rid25">25</a>]. Pentamidine has poor cerebrospinal fluid penetration; therefore, its use is limited to first-stage trypanosomiasis (without central nervous system involvement). </p><p>Adverse reactions of parenteral <a class="drug drug_general" data-topicid="9752" href="/z/d/drug information/9752.html" rel="external">pentamidine</a> are common, including reversible nephrotoxicity, acute hypotension, pancreatitis, hypoglycemia, cardiac arrhythmias, blood dyscrasias, and sterile abscesses at the injection site [<a href="#rid26">26,27</a>]. </p><p>Aerosolized <a class="drug drug_general" data-topicid="9752" href="/z/d/drug information/9752.html" rel="external">pentamidine</a> used for the prophylaxis of <em>Pneumocystis </em>pneumonia in susceptible patients is associated with local adverse effects, including sore throat, oral paresthesias, metallic taste, cough, and bronchospasm.</p><p class="headingAnchor" id="H15"><span class="h1">PYRIMETHAMINE</span><span class="headingEndMark"> — </span>Pyrimethamine-sulfadiazine is used in the treatment of toxoplasmosis. The high doses required for this treatment often result in significant folate deficiency, requiring folinic acid replacement. Abdominal symptoms and rashes are also common. (See  <a class="medical medical_review" href="/z/d/html/3710.html" rel="external">"Toxoplasmosis in patients with HIV"</a>.)</p><p>Pyrimethamine-dapsone is used for prophylaxis of <em>Pneumocystis </em>pneumonia. (See  <a class="medical medical_review" href="/z/d/html/1406.html" rel="external">"Epidemiology, clinical manifestations, and diagnosis of Pneumocystis pneumonia in patients without HIV"</a> and  <a class="medical medical_review" href="/z/d/html/3709.html" rel="external">"Treatment and prevention of Pneumocystis infection in patients with HIV"</a>.)</p><p><a class="drug drug_general" data-topicid="9841" href="/z/d/drug information/9841.html" rel="external">Pyrimethamine</a> is effective for acute treatment and maintenance suppression of <em>Isospora belli</em> infections [<a href="#rid28">28</a>]. (See  <a class="medical medical_review" href="/z/d/html/16969.html" rel="external">"Management of Cystoisospora (Isospora) infections"</a>.)</p><p class="headingAnchor" id="H16"><span class="h1">QUINACRINE</span><span class="headingEndMark"> — </span>Quinacrine is an acridine dye with activity against giardiasis. It is well absorbed and may impart a yellow color to the urine and rarely to the skin or sclerae. Adverse effects include headache, dizziness, vomiting, diarrhea, and, less commonly, psychotic episodes.</p><p class="headingAnchor" id="H17"><span class="h1">SPIRAMYCIN</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="10092" href="/z/d/drug information/10092.html" rel="external">Spiramycin</a> has activity against toxoplasmosis and is an alternative to antifolates. In the setting of intrauterine infection, spiramycin is administered throughout pregnancy until delivery. (See  <a class="medical medical_review" href="/z/d/html/6756.html" rel="external">"Toxoplasmosis and pregnancy"</a>.)</p><p class="headingAnchor" id="H19"><span class="h1">SURAMIN</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="10291" href="/z/d/drug information/10291.html" rel="external">Suramin</a> is a polysulfonated naphthylamine derivative of urea. The mechanism of action is not fully understood; it is thought to act by inhibition of enzymes associated with DNA metabolism and protein synthesis in trypanosomal parasites. Suramin is used for treating the early stage of East African trypanosomiasis due to <em>T. b. rhodesiense</em>. It must be given intravenously and is excreted very slowly. Adverse effects are common and can be severe, including cutaneous eruptions, vomiting, paresthesias, photophobia, peripheral neuropathy, anaphylaxis, and renal damage. (See  <a class="medical medical_review" href="/z/d/html/5697.html" rel="external">"Human African trypanosomiasis: Epidemiology, clinical manifestations, and diagnosis"</a>.)</p><p class="headingAnchor" id="H20"><span class="h1">TETRACYCLINE</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9986" href="/z/d/drug information/9986.html" rel="external">Tetracycline</a> has activity against <em>B. coli</em> and <em>D. fragilis</em> enteric infections. (See  <a class="medical medical_review" href="/z/d/html/5726.html" rel="external">"Balantidium coli infection"</a> and  <a class="medical medical_review" href="/z/d/html/5720.html" rel="external">"Dientamoeba fragilis"</a>.)</p><p class="headingAnchor" id="H21"><span class="h1">TINIDAZOLE</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="10205" href="/z/d/drug information/10205.html" rel="external">Tinidazole</a> has activity against amebiasis, giardiasis, and vaginal trichomoniasis and may be better tolerated than <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">metronidazole</a>. (See  <a class="medical medical_review" href="/z/d/html/5727.html" rel="external">"Intestinal Entamoeba histolytica amebiasis"</a> and  <a class="medical medical_review" href="/z/d/html/5728.html" rel="external">"Extraintestinal Entamoeba histolytica amebiasis"</a> and  <a class="medical medical_review" href="/z/d/html/6024.html" rel="external">"Giardiasis: Treatment and prevention"</a> and  <a class="medical medical_review" href="/z/d/html/5453.html" rel="external">"Trichomoniasis: Clinical manifestations and diagnosis"</a>.)</p><p class="headingAnchor" id="H22"><span class="h1">TRIMETHOPRIM-SULFAMETHOXAZOLE</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9785" href="/z/d/drug information/9785.html" rel="external">Trimethoprim-sulfamethoxazole</a> (TMP-SMX) is the preferred treatment for <em>Pneumocystis </em>pneumonia and is used for prophylaxis against this infection in immunocompromised patients. (See  <a class="medical medical_review" href="/z/d/html/1406.html" rel="external">"Epidemiology, clinical manifestations, and diagnosis of Pneumocystis pneumonia in patients without HIV"</a> and  <a class="medical medical_review" href="/z/d/html/3709.html" rel="external">"Treatment and prevention of Pneumocystis infection in patients with HIV"</a>.)</p><p>TMP-SMX is effective in treating enteric infections with <em>Isospora belli</em> and is used as long-term maintenance therapy to prevent relapse in patients with AIDS. (See  <a class="medical medical_review" href="/z/d/html/5725.html" rel="external">"Epidemiology, clinical manifestations, and diagnosis of Cystoisospora (Isospora) infections"</a>.)</p><p>TMP-SMX also has activity against enteric infection due to <em>Cyclospora</em>. (See  <a class="medical medical_review" href="/z/d/html/5724.html" rel="external">"Cyclospora infection"</a>.)</p><p>Adverse effects are primarily due to the sulfamethoxazole and include skin, liver, and bone marrow toxicity.</p><p class="headingAnchor" id="H4205629"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment for giardiasis</strong> – Antiprotozoal agents with activity against giardiasis include <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">metronidazole</a>, <a class="drug drug_general" data-topicid="10105" href="/z/d/drug information/10105.html" rel="external">nitazoxanide</a>, <a class="drug drug_general" data-topicid="10205" href="/z/d/drug information/10205.html" rel="external">tinidazole</a>, furazolidone, and quinacrine. (See <a class="local">'Metronidazole'</a> above and <a class="local">'Nitazoxanide'</a> above and <a class="local">'Tinidazole'</a> above and <a class="local">'Furazolidone'</a> above and <a class="local">'Quinacrine'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment for </strong><strong><em>pneumocystis</em></strong><strong> pneumonia</strong> – Antiprotozoal agents with activity against <em>Pneumocystis</em> include <a class="drug drug_general" data-topicid="9785" href="/z/d/drug information/9785.html" rel="external">trimethoprim-sulfamethoxazole</a>, <a class="drug drug_general" data-topicid="8957" href="/z/d/drug information/8957.html" rel="external">atovaquone</a>, <a class="drug drug_general" data-topicid="9752" href="/z/d/drug information/9752.html" rel="external">pentamidine</a>, and pyrimethamine-dapsone. (See <a class="local">'Trimethoprim-sulfamethoxazole'</a> above and <a class="local">'Atovaquone'</a> above and <a class="local">'Pentamidine'</a> above and <a class="local">'Pyrimethamine'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment for amebiasis</strong> – Antiprotozoal agents with activity against amebiasis include <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">metronidazole</a>, <a class="drug drug_general" data-topicid="10205" href="/z/d/drug information/10205.html" rel="external">tinidazole</a>, and <a class="drug drug_general" data-topicid="9742" href="/z/d/drug information/9742.html" rel="external">paromomycin</a>. (See <a class="local">'Metronidazole'</a> above and <a class="local">'Tinidazole'</a> above and <a class="local">'Paromomycin'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment for </strong><strong><em>Dientamoeba fragilis</em></strong><strong> and </strong><strong><em>Balantidium coli</em></strong> – <a class="drug drug_general" data-topicid="9986" href="/z/d/drug information/9986.html" rel="external">Tetracycline</a> and iodoquinol have activity against both <em>Dientamoeba fragilis</em> and <em>Balantidium coli</em>. (See <a class="local">'Tetracycline'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Details of treatment regimens</strong> – The use of antiprotozoal therapies for treatment of specific protozoal infections is discussed in detail separately. (See related topics.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li class="breakAll">Drugs for Parasitic Infections, 3rd ed, The Medical Letter, New Rochelle, NY 2013.</li><li class="breakAll">Leder K, McGuinness SL. Antiparasitic agents. In: Manual of Clinical Microbiology, 12, ASM Press, Washington, DC 2023. p.15.</li><li><a class="nounderline abstract_t">Lacey E. Mode of action of benzimidazoles. Parasitol Today 1990; 6:112.</a></li><li><a class="nounderline abstract_t">Blanshard C, Ellis DS, Tovey DG, et al. Treatment of intestinal microsporidiosis with albendazole in patients with AIDS. AIDS 1992; 6:311.</a></li><li><a class="nounderline abstract_t">Molina JM, Oksenhendler E, Beauvais B, et al. Disseminated microsporidiosis due to Septata intestinalis in patients with AIDS: clinical features and response to albendazole therapy. J Infect Dis 1995; 171:245.</a></li><li><a class="nounderline abstract_t">Weber R, Sauer B, Spycher MA, et al. Detection of Septata intestinalis in stool specimens and coprodiagnostic monitoring of successful treatment with albendazole. Clin Infect Dis 1994; 19:342.</a></li><li><a class="nounderline abstract_t">Dieterich DT, Lew EA, Kotler DP, et al. Treatment with albendazole for intestinal disease due to Enterocytozoon bieneusi in patients with AIDS. J Infect Dis 1994; 169:178.</a></li><li><a class="nounderline abstract_t">Asmuth DM, DeGirolami PC, Federman M, et al. Clinical features of microsporidiosis in patients with AIDS. Clin Infect Dis 1994; 18:819.</a></li><li><a class="nounderline abstract_t">Molina JM, Chastang C, Goguel J, et al. Albendazole for treatment and prophylaxis of microsporidiosis due to Encephalitozoon intestinalis in patients with AIDS: a randomized double-blind controlled trial. J Infect Dis 1998; 177:1373.</a></li><li><a class="nounderline abstract_t">Leder K, Ryan N, Spelman D, Crowe SM. Microsporidial disease in HIV-infected patients: a report of 42 patients and review of the literature. Scand J Infect Dis 1998; 30:331.</a></li><li><a class="nounderline abstract_t">Conteas CN, Berlin OG, Speck CE, et al. Modification of the clinical course of intestinal microsporidiosis in acquired immunodeficiency syndrome patients by immune status and anti-human immunodeficiency virus therapy. Am J Trop Med Hyg 1998; 58:555.</a></li><li><a class="nounderline abstract_t">Haile LG, Flaherty JF. Atovaquone: a review. Ann Pharmacother 1993; 27:1488.</a></li><li><a class="nounderline abstract_t">Dixon R, Pozniak AL, Watt HM, et al. Single-dose and steady-state pharmacokinetics of a novel microfluidized suspension of atovaquone in human immunodeficiency virus-seropositive patients. Antimicrob Agents Chemother 1996; 40:556.</a></li><li><a class="nounderline abstract_t">Denise H, Barrett MP. Uptake and mode of action of drugs used against sleeping sickness. Biochem Pharmacol 2001; 61:1.</a></li><li><a class="nounderline abstract_t">Kingsnorth AN. The chemotherapeutic potential of polyamine antimetabolites. Ann R Coll Surg Engl 1986; 68:76.</a></li><li class="breakAll">European Medicines Agency. Assessment report: Fexinidazole Winthrop. https://www.ema.europa.eu/en/documents/outside-eu-assessment-report/fexinidazole-winthrop-assessment-report_en.pdf (Accessed on July 05, 2023).</li><li><a class="nounderline abstract_t">Pelfrene E, Harvey Allchurch M, Ntamabyaliro N, et al. The European Medicines Agency's scientific opinion on oral fexinidazole for human African trypanosomiasis. PLoS Negl Trop Dis 2019; 13:e0007381.</a></li><li class="breakAll">US Food and Drug Administration. Fexinidazole. https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=513915 (Accessed on July 05, 2023).</li><li><a class="nounderline abstract_t">Beauvais B, Sarfati C, Challier S, Derouin F. In vitro model to assess effect of antimicrobial agents on Encephalitozoon cuniculi. Antimicrob Agents Chemother 1994; 38:2440.</a></li><li><a class="nounderline abstract_t">Altamirano A, Bondani A. Adverse reactions to furazolidone and other drugs. A comparative review. Scand J Gastroenterol Suppl 1989; 169:70.</a></li><li><a class="nounderline abstract_t">de Andrade AL, Zicker F, de Oliveira RM, et al. Randomised trial of efficacy of benznidazole in treatment of early Trypanosoma cruzi infection. Lancet 1996; 348:1407.</a></li><li><a class="nounderline abstract_t">Wang CC. Molecular mechanisms and therapeutic approaches to the treatment of African trypanosomiasis. Annu Rev Pharmacol Toxicol 1995; 35:93.</a></li><li><a class="nounderline abstract_t">Castro JA, Diaz de Toranzo EG. Toxic effects of nifurtimox and benznidazole, two drugs used against American trypanosomiasis (Chagas' disease). Biomed Environ Sci 1988; 1:19.</a></li><li class="breakAll">Leder K, McGuinness SL, Weller PF. Antiparasitic agents. In: Manual of Clinical Microbiology, 12, Jorgenson JH, Pfaller MA, Carroll KC, et al (Eds), American Society of Microbiology, Washington 2019. p.2645.</li><li><a class="nounderline abstract_t">Sands M, Kron MA, Brown RB. Pentamidine: a review. Rev Infect Dis 1985; 7:625.</a></li><li><a class="nounderline abstract_t">O'Brien JG, Dong BJ, Coleman RL, et al. A 5-year retrospective review of adverse drug reactions and their risk factors in human immunodeficiency virus-infected patients who were receiving intravenous pentamidine therapy for Pneumocystis carinii pneumonia. Clin Infect Dis 1997; 24:854.</a></li><li><a class="nounderline abstract_t">Salamone FR, Cunha BA. Update on pentamidine for the treatment of Pneumocystis carinii pneumonia. Clin Pharm 1988; 7:501.</a></li><li><a class="nounderline abstract_t">Weiss LM, Perlman DC, Sherman J, et al. Isospora belli infection: treatment with pyrimethamine. Ann Intern Med 1988; 109:474.</a></li></ol></div><div id="topicVersionRevision">Topic 489 Version 27.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="javascript:alert('بدون لینک');" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Drugs for Parasitic Infections, 3rd ed, The Medical Letter, New Rochelle, NY 2013.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="javascript:alert('بدون لینک');" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Leder K, McGuinness SL. Antiparasitic agents. In: Manual of Clinical Microbiology, 12, ASM Press, Washington, DC 2023. p.15.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15463312" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Mode of action of benzimidazoles.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1567576" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Treatment of intestinal microsporidiosis with albendazole in patients with AIDS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7798674" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Disseminated microsporidiosis due to Septata intestinalis in patients with AIDS: clinical features and response to albendazole therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7986914" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Detection of Septata intestinalis in stool specimens and coprodiagnostic monitoring of successful treatment with albendazole.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8277179" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Treatment with albendazole for intestinal disease due to Enterocytozoon bieneusi in patients with AIDS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7915548" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Clinical features of microsporidiosis in patients with AIDS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9593027" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Albendazole for treatment and prophylaxis of microsporidiosis due to Encephalitozoon intestinalis in patients with AIDS: a randomized double-blind controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9817510" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Microsporidial disease in HIV-infected patients: a report of 42 patients and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9598440" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Modification of the clinical course of intestinal microsporidiosis in acquired immunodeficiency syndrome patients by immune status and anti-human immunodeficiency virus therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8305784" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Atovaquone: a review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8851570" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Single-dose and steady-state pharmacokinetics of a novel microfluidized suspension of atovaquone in human immunodeficiency virus-seropositive patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11137702" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Uptake and mode of action of drugs used against sleeping sickness.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3082276" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : The chemotherapeutic potential of polyamine antimetabolites.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3082276" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : The chemotherapeutic potential of polyamine antimetabolites.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31246956" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : The European Medicines Agency's scientific opinion on oral fexinidazole for human African trypanosomiasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31246956" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : The European Medicines Agency's scientific opinion on oral fexinidazole for human African trypanosomiasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7840584" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : In vitro model to assess effect of antimicrobial agents on Encephalitozoon cuniculi.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2694347" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Adverse reactions to furazolidone and other drugs. A comparative review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8937280" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Randomised trial of efficacy of benznidazole in treatment of early Trypanosoma cruzi infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7598514" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Molecular mechanisms and therapeutic approaches to the treatment of African trypanosomiasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3151755" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Toxic effects of nifurtimox and benznidazole, two drugs used against American trypanosomiasis (Chagas' disease).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3151755" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Toxic effects of nifurtimox and benznidazole, two drugs used against American trypanosomiasis (Chagas' disease).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3903942" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Pentamidine: a review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9142782" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : A 5-year retrospective review of adverse drug reactions and their risk factors in human immunodeficiency virus-infected patients who were receiving intravenous pentamidine therapy for Pneumocystis carinii pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3046830" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Update on pentamidine for the treatment of Pneumocystis carinii pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3261956" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Isospora belli infection: treatment with pyrimethamine.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
